TAK-070   Click here for help

GtoPdb Ligand ID: 6940

Compound class: Synthetic organic
Comment: TAK-070 from Takeda shows partial reduction in Aβ as well as increase in sAPPα in animal models. The noncompetitive BACE1 inhibition may be sufficient to modify amyloid pathology and ameliorate cognitive deficits in Alzheimer's Diseases without causing potential adverse events by complete BACE1 ablation.[1]
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 12.47
Molecular weight 385.24
XLogP 6.92
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN(CCC1CCc2c(C1)ccc(c2)OCc1ccc(cc1)c1ccccc1)C
Isomeric SMILES CN(CC[C@@H]1CCc2c(C1)ccc(c2)OCc1ccc(cc1)c1ccccc1)C
InChI InChI=1S/C27H31NO/c1-28(2)17-16-21-8-13-26-19-27(15-14-25(26)18-21)29-20-22-9-11-24(12-10-22)23-6-4-3-5-7-23/h3-7,9-12,14-15,19,21H,8,13,16-18,20H2,1-2H3/t21-/m0/s1
InChI Key SETMAZMOXYOEJA-NRFANRHFSA-N
No information available.
Summary of Clinical Use Click here for help
Takeda will not further develop this compound for Alzheimer's Disease but has transfered TAK-070 to the University of Tokyo Hospital (press release) which may progress this to clinical testing.